1. Trimethylamine N-oxide is associated with impaired cognitive function in patients with atrial fibrillation. (3rd October 2022) Authors: Ziswiler, T; Luciani, M; Vanetta, C; Springer, A; Diteepeng, T; Von Eckardstein, A; Mueller, D; Barbagallo, M; Conen, D; Rodondi, N; Moschovitis, G; Osswald, S; Kuehne, M; Bonati, L H; Beer, J H Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Trimethylamine-N-oxide (TMAO) is associated with cardiovascular mortality and vascular brain lesions in patients with atrial fibrillation. (14th October 2021) Authors: Luciani, M; Mueller, D; Vanetta, C; Diteepeng, T; Von Eckardstein, A; Aeschbacher, S; Rodondi, N; Moschovitis, G; Reichlin, T; Bonati, L; Luescher, T.F; Kuehne, M; Osswald, S; Conen, D; Beer, J.H Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗